Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery
Purpose The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address t...
Saved in:
| Published in | Obesity surgery Vol. 34; no. 4; pp. 1217 - 1223 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
New York
Springer US
01.04.2024
Springer Nature B.V |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0960-8923 1708-0428 1708-0428 |
| DOI | 10.1007/s11695-024-07100-z |
Cover
| Abstract | Purpose
The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.
Materials and Methods
The study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (
n
= 1443; 60%) and those who did not (
n
= 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.
Results
There were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment;
p
= 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%;
p
= 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.
Conclusion
There were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery.
Graphical Abstract |
|---|---|
| AbstractList | The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.
The study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (n = 1443; 60%) and those who did not (n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.
There were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.
There were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery. Purpose The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery. Materials and Methods The study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge ( n = 1443; 60%) and those who did not ( n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups. Results There were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding. Conclusion There were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery. Graphical Abstract The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.PURPOSEThe utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.The study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (n = 1443; 60%) and those who did not (n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.MATERIALS AND METHODSThe study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (n = 1443; 60%) and those who did not (n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.There were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.RESULTSThere were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.There were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery.CONCLUSIONThere were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery. PurposeThe utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.Materials and MethodsThe study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (n = 1443; 60%) and those who did not (n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.ResultsThere were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.ConclusionThere were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery. |
| Author | Guzman-Pruneda, Francisco A. Crum, Robert W. Garcia, Ambar Krikhely, Abraham Chen, Theresa Bessler, Marc |
| Author_xml | – sequence: 1 givenname: Francisco A. orcidid: 0000-0002-1001-9106 surname: Guzman-Pruneda fullname: Guzman-Pruneda, Francisco A. email: fg2550@cumc.columbia.edu organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion – sequence: 2 givenname: Ambar surname: Garcia fullname: Garcia, Ambar organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion – sequence: 3 givenname: Robert W. surname: Crum fullname: Crum, Robert W. organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion – sequence: 4 givenname: Theresa surname: Chen fullname: Chen, Theresa organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion – sequence: 5 givenname: Abraham surname: Krikhely fullname: Krikhely, Abraham organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion – sequence: 6 givenname: Marc surname: Bessler fullname: Bessler, Marc organization: Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38409623$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxS1URLeFL8ABWeLCJTC2kzg5llL-SJWoROFqeZMx6yqxF9upuv30TNkCUg892Jbs3xvPvHfEDkIMyNhLAW8FgH6XhWj7pgJZV6Dpprp9wlZCQ1dBLbsDtoK-harrpTpkRzlfAUjRSvmMHaqupjepVsye3RQMI478IubCP_g8bGz6ifwixe1mN9kbn7mLif_AEJfMLzcpzuuItCafZ8LwGkPxMfATVzDx9zZ5W5If-LeF6qTdc_bU2Snji_vzmH3_eHZ5-rk6__rpy-nJeTUo3ZRKjH07jINSVrga16p2buxkD80IjaNNjmvQNYrBSk0CLRoFTmk7aARB06tj9mZfd5virwVzMTMNg9NkA1LnRvZK1krXfU_o6wfoVVxSoO6MAnJGq1a3RL26p5b1jKPZJj_btDN_zSNA7oEhxZwTun-IAHOXkNknZCgh8ychc0ui7oFo8MXeGViS9dPjUrWXZvonkLf_235E9Rs3mKWS |
| CitedBy_id | crossref_primary_10_1007_s11695_025_07721_y crossref_primary_10_1007_s11695_025_07780_1 |
| Cites_doi | 10.1016/j.soard.2018.01.008 10.1001/archsurg.2012.2298 10.1007/s00464-008-0031-9 10.1016/j.soard.2022.06.284 10.1007/s11695-007-9382-x 10.1097/SLA.0000000000001686 10.1007/s11695-018-03643-0 10.1055/s-0031-1297369 10.1007/s11605-018-3951-2 10.1080/17474086.2019.1634542 10.1007/s11695-020-04764-1 10.1111/bcp.13243 10.1007/s00464-019-06911-x 10.1016/j.soard.2020.05.022 10.1016/j.soard.2010.12.008 10.1111/obr.12647 10.1007/s11695-018-3593-1 10.1177/000313480507100508 10.1007/s11695-016-2059-6 10.1007/s11695-023-06471-z.10.1007/s11695-023-06471-z 10.1016/j.soard.2019.02.017 10.1016/j.soard.2022.12.038 10.1007/s11695-022-06051-7 10.1007/s00464-019-07134-w 10.1111/jth.14263 10.1016/j.thromres.2017.11.006 10.1016/j.jsps.2022.07.008 10.1016/j.soard.2021.10.023 10.3349/ymj.2019.60.7.626 10.1177/1076029609342093 10.1007/s11695-018-3429-z 10.1016/j.soard.2017.12.004 10.1007/s11695-018-3415-5 10.1016/j.disamonth.2005.02.003 10.1007/s00464-018-6231-z 10.5217/ir.2018.16.3.416 10.1056/NEJMoa0901836 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. – notice: 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8AO 8C1 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1007/s11695-024-07100-z |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Proquest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic ProQuest One Academic Middle East (New) |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1708-0428 |
| EndPage | 1223 |
| ExternalDocumentID | 38409623 10_1007_s11695_024_07100_z |
| Genre | Journal Article |
| GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 123 1N0 1SB 203 28- 29N 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 3V. 4.4 406 408 40D 40E 53G 5RE 5VS 67Z 6NX 7X7 88E 8AO 8C1 8FI 8FJ 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AAQQT AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABQSL ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACAOD ACBXY ACDTI ACGFS ACHSB ACHVE ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACUDM ACZOJ ADBBV ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFQL AEGAL AEGNC AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFEXP AFJLC AFKRA AFLOW AFQWF AFWTZ AFZKB AGAYW AGDGC AGGDS AGJBK AGMZJ AGQEE AGQMX AGRTI AGVAE AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ AKMHD ALIPV ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBWZM BDATZ BENPR BGNMA BPHCQ BSONS BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DNIVK DPUIP DU5 EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GRRUI H13 HF~ HG5 HG6 HMCUK HMJXF HRMNR HVGLF HZ~ IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZQ I~X I~Z J-C J0Z JBSCW JZLTJ KDC KOV KPH LLZTM M1P M4Y MA- N2Q NDZJH NF0 NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJN SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z45 Z7U Z7W Z7X Z82 Z83 Z87 Z8O Z8Q Z8V Z91 Z92 ZMTXR ZOVNA ZXE ~EX AAPKM AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC ADHKG AEZWR AFDZB AFHIU AFOHR AGQPQ AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION PHGZM PHGZT PJZUB PPXIY PUEGO CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c375t-1d96cdc33a1f4eb34ffd82905d05f5d02db074e1ca2737571530f37ac7e017103 |
| IEDL.DBID | U2A |
| ISSN | 0960-8923 1708-0428 |
| IngestDate | Thu Oct 02 06:03:01 EDT 2025 Tue Oct 07 05:59:13 EDT 2025 Thu Apr 03 07:06:03 EDT 2025 Wed Oct 01 02:14:26 EDT 2025 Thu Apr 24 23:07:07 EDT 2025 Fri Feb 21 02:41:49 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | DVT Extended prophylaxis VTE Bariatric surgery Apixaban |
| Language | English |
| License | 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c375t-1d96cdc33a1f4eb34ffd82905d05f5d02db074e1ca2737571530f37ac7e017103 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1001-9106 |
| PMID | 38409623 |
| PQID | 3040973676 |
| PQPubID | 55143 |
| PageCount | 7 |
| ParticipantIDs | proquest_miscellaneous_2932437499 proquest_journals_3040973676 pubmed_primary_38409623 crossref_primary_10_1007_s11695_024_07100_z crossref_citationtrail_10_1007_s11695_024_07100_z springer_journals_10_1007_s11695_024_07100_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20240400 2024-04-00 2024-Apr 20240401 |
| PublicationDateYYYYMMDD | 2024-04-01 |
| PublicationDate_xml | – month: 4 year: 2024 text: 20240400 |
| PublicationDecade | 2020 |
| PublicationPlace | New York |
| PublicationPlace_xml | – name: New York – name: United States |
| PublicationSubtitle | The Journal of Metabolic Surgery and Allied Care |
| PublicationTitle | Obesity surgery |
| PublicationTitleAbbrev | OBES SURG |
| PublicationTitleAlternate | Obes Surg |
| PublicationYear | 2024 |
| Publisher | Springer US Springer Nature B.V |
| Publisher_xml | – name: Springer US – name: Springer Nature B.V |
| References | Chang, Freeman, Lee (CR14) 2018; 19 Welbourn, Hollyman, Kinsman, Dixon, Liem, Ottosson, Ramos, Våge, Al-Sabah, Brown, Cohen, Walton, Himpens (CR1) 2019; 29 Caprini (CR19) 2005; 51 Surve, Potts, Cottam (CR21) 2022; 32 Birkmeyer, Finks, Carlin (CR17) 2012; 147 Rottenstreich, Barkai, Arad, Raccah, Kalish (CR38) 2018; 163 Altieri, Yang, Hajagos (CR10) 2018; 32 Dang, Szeto, Elnahas (CR18) 2020; 34 Ceha, van Wezenbeek, Versteegden, Smulders, Nienhuijs (CR26) 2018; 28 Chung, Strassle, Schlottmann, Patti, Duke, Farrell (CR15) 2019; 23 Kröll, Stirnimann, Vogt (CR39) 2017; 83 Muñoz-Atienza, Gil-Rendo, Amo-Salas, Núñez-Guerrero, Martín-Fernández (CR30) 2018; 14 Aminian, Andalib, Khorgami (CR7) 2017; 265 Raftopoulos, Martindale, Cronin, Steinberg (CR35) 2008; 22 Spaniolas, Kasten, Celio, Burruss, Pories (CR24) 2016; 26 Altawil, Alkofide, Almohaini, Alobeed, Alhossan (CR36) 2022; 30 Sánchez-Pernaute, Rubio, Pérez, Marcuello, Torres, Pérez-Aguirre (CR25) 2020; 16 Clapp, Ponce, DeMaria (CR29) 2022; 18 Tseng, Kolesar, Handa (CR33) 2018; 16 Abuoglu, Müftüoğlu, Odabaşı (CR34) 2019; 29 Allman-Farinelli (CR5) 2011; 37 Hamadi, Marlow, Nassereddine, Taher, Finianos (CR16) 2019; 12 Dijkhorst, Boerboom, Janssen (CR27) 2018; 28 CR2 Daigle, Brethauer, Tu, Petrick, Morton, Schauer, Aminian (CR12) 2018; 14 Stein, Hull, Matta, Yaekoub (CR6) 2010; 16 Jiang, Meng, Guo (CR13) 2019; 60 Aminian, Vosburg, Altieri, Hinojosa, Khorgami (CR11) 2022; 18 Winegar, Sherif, Pate, DeMaria (CR8) 2011; 7 Clark, Helm, Gould (CR32) 2019; 15 Ando, Fujiya, Nomura (CR3) 2018; 16 Antanavicius, Katsichtis, Alswealmeen, Assali (CR28) 2020; 30 CR22 Swartz, Hood, Swartz, Gupta (CR37) 2023; 33 Aminian, Andalib, Khorgami (CR4) 2017; 265 Giannopoulos, KalantarMotamedi, Athanasiadis (CR20) 2023; 19 Gambhir, Inaba, Alizadeh (CR23) 2020; 34 Poulose, Griffin, Zhu (CR9) 2005; 71 Ojo, Asiyanbola, Valin, Reinhold (CR31) 2008; 18 R Welbourn (7100_CR1) 2019; 29 DE Swartz (7100_CR37) 2023; 33 G Antanavicius (7100_CR28) 2020; 30 A Rottenstreich (7100_CR38) 2018; 163 V Muñoz-Atienza (7100_CR30) 2018; 14 I Raftopoulos (7100_CR35) 2008; 22 P Ojo (7100_CR31) 2008; 18 7100_CR22 MA Allman-Farinelli (7100_CR5) 2011; 37 A Aminian (7100_CR11) 2022; 18 7100_CR2 R Hamadi (7100_CR16) 2019; 12 NJ Birkmeyer (7100_CR17) 2012; 147 PJ Dijkhorst (7100_CR27) 2018; 28 MS Altieri (7100_CR10) 2018; 32 SH Chang (7100_CR14) 2018; 19 A Surve (7100_CR21) 2022; 32 EK Tseng (7100_CR33) 2018; 16 DA Winegar (7100_CR8) 2011; 7 H Jiang (7100_CR13) 2019; 60 CR Daigle (7100_CR12) 2018; 14 S Giannopoulos (7100_CR20) 2023; 19 S Gambhir (7100_CR23) 2020; 34 A Sánchez-Pernaute (7100_CR25) 2020; 16 JA Caprini (7100_CR19) 2005; 51 K Spaniolas (7100_CR24) 2016; 26 LN Clark (7100_CR32) 2019; 15 PD Stein (7100_CR6) 2010; 16 HH Abuoglu (7100_CR34) 2019; 29 CMM Ceha (7100_CR26) 2018; 28 A Aminian (7100_CR7) 2017; 265 BK Poulose (7100_CR9) 2005; 71 B Clapp (7100_CR29) 2022; 18 E Altawil (7100_CR36) 2022; 30 AY Chung (7100_CR15) 2019; 23 K Ando (7100_CR3) 2018; 16 JT Dang (7100_CR18) 2020; 34 A Aminian (7100_CR4) 2017; 265 D Kröll (7100_CR39) 2017; 83 |
| References_xml | – volume: 14 start-page: 652 issue: 5 year: 2018 end-page: 657 ident: CR12 article-title: Which postoperative complications matter most after bariatric surgery? Prioritizing quality improvement efforts to improve national outcomes publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2018.01.008 – volume: 147 start-page: 994 issue: 11 year: 2012 end-page: 998 ident: CR17 article-title: Comparative effectiveness of unfractionated and low-molecular-weight heparin for prevention of venous thromboembolism following bariatric surgery publication-title: Arch Surg doi: 10.1001/archsurg.2012.2298 – ident: CR22 – volume: 22 start-page: 2384 issue: 11 year: 2008 end-page: 2391 ident: CR35 article-title: The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial publication-title: Surg Endosc doi: 10.1007/s00464-008-0031-9 – volume: 18 start-page: 1134 issue: 9 year: 2022 end-page: 1140 ident: CR29 article-title: American Society for Metabolic and Bariatric Surgery 2020 estimate of metabolic and bariatric procedures performed in the United States publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2022.06.284 – volume: 18 start-page: 791 issue: 7 year: 2008 end-page: 796 ident: CR31 article-title: Post discharge prophylactic anticoagulation in gastric bypass patient-how safe? publication-title: Obes Surg doi: 10.1007/s11695-007-9382-x – volume: 265 start-page: 143 issue: 1 year: 2017 end-page: 150 ident: CR7 article-title: Who should get extended thromboprophylaxis after bariatric surgery?: A risk assessment tool to guide indications for post-discharge pharmacoprophylaxis publication-title: Ann Surg doi: 10.1097/SLA.0000000000001686 – volume: 29 start-page: 729 issue: 2 year: 2019 end-page: 734 ident: CR34 article-title: A new protocol for venous thromboembolism prophylaxis in bariatric surgery publication-title: Obes Surg doi: 10.1007/s11695-018-03643-0 – ident: CR2 – volume: 37 start-page: 903 issue: 8 year: 2011 end-page: 907 ident: CR5 article-title: Obesity and venous thrombosis: a review publication-title: Semin Thromb Hemost doi: 10.1055/s-0031-1297369 – volume: 23 start-page: 1362 issue: 7 year: 2019 end-page: 1372 ident: CR15 article-title: Trends in utilization and relative complication rates of bariatric procedures publication-title: J Gastrointest Surg doi: 10.1007/s11605-018-3951-2 – volume: 12 start-page: 763 issue: 9 year: 2019 end-page: 771 ident: CR16 article-title: Bariatric venous thromboembolism prophylaxis: an update on the literature publication-title: Expert Rev Hematol doi: 10.1080/17474086.2019.1634542 – volume: 30 start-page: 3961 issue: 10 year: 2020 end-page: 3967 ident: CR28 article-title: Three hundred four robotically assisted biliopancreatic diversion with duodenal switch operations with gradual robotic approach implementation: short-term outcomes, complication profile, and lessons learned publication-title: Obes Surg doi: 10.1007/s11695-020-04764-1 – volume: 83 start-page: 1466 issue: 7 year: 2017 end-page: 1475 ident: CR39 article-title: Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13243 – volume: 34 start-page: 1366 issue: 3 year: 2020 end-page: 1375 ident: CR18 article-title: Canadian consensus statement: enhanced recovery after surgery in bariatric surgery publication-title: Surg Endosc doi: 10.1007/s00464-019-06911-x – volume: 16 start-page: 1491 issue: 10 year: 2020 end-page: 1496 ident: CR25 article-title: Single-anastomosis duodenoileal bypass as a revisional or second-step operation after sleeve gastrectomy publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2020.05.022 – volume: 7 start-page: 181 issue: 2 year: 2011 end-page: 188 ident: CR8 article-title: Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2010.12.008 – volume: 19 start-page: 529 issue: 4 year: 2018 end-page: 537 ident: CR14 article-title: Early major complications after bariatric surgery in the USA, 2003–2014: a systematic review and meta-analysis publication-title: Obes Rev doi: 10.1111/obr.12647 – volume: 29 start-page: 782 issue: 3 year: 2019 end-page: 795 ident: CR1 article-title: Bariatric surgery worldwide: Baseline demographic description and one-year outcomes from the fourth IFSO global registry report 2018 publication-title: Obes Surg doi: 10.1007/s11695-018-3593-1 – volume: 71 start-page: 406 issue: 5 year: 2005 end-page: 413 ident: CR9 article-title: National analysis of adverse patient safety for events in bariatric surgery publication-title: Am Surg doi: 10.1177/000313480507100508 – volume: 26 start-page: 900 issue: 4 year: 2016 end-page: 903 ident: CR24 article-title: Postoperative follow-up after bariatric surgery: effect on weight loss publication-title: Obes Surg doi: 10.1007/s11695-016-2059-6 – volume: 33 start-page: 1026 issue: 4 year: 2023 end-page: 1031 ident: CR37 article-title: 30-day post-discharge prophylaxis with rivaroxaban prevents porto-mesenteric venous thrombosis following laparoscopic sleeve gastrectomy publication-title: Obes Surg doi: 10.1007/s11695-023-06471-z.10.1007/s11695-023-06471-z – volume: 15 start-page: 703 issue: 5 year: 2019 end-page: 707 ident: CR32 article-title: Practice patterns regarding post-discharge chemoprophylaxis for venous thromboembolism following bariatric surgery in the United States publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2019.02.017 – volume: 19 start-page: 799 issue: 8 year: 2023 end-page: 807 ident: CR20 article-title: Venous thromboembolism (VTE) prophylaxis after bariatric surgery: a national survey of MBSAQIP director practices publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2022.12.038 – volume: 32 start-page: 1 issue: 7 year: 2022 end-page: 6 ident: CR21 article-title: The safety and efficacy of apixaban (Eliquis) in 5017 post-bariatric patients with 95.3% follow-up: a multicenter study publication-title: Obes Surg doi: 10.1007/s11695-022-06051-7 – volume: 34 start-page: 3521 issue: 8 year: 2020 end-page: 3526 ident: CR23 article-title: Venous thromboembolism risk for the contemporary bariatric surgeon publication-title: Surg Endosc doi: 10.1007/s00464-019-07134-w – volume: 16 start-page: 2008 issue: 10 year: 2018 end-page: 2015 ident: CR33 article-title: Weight-adjusted tinzaparin for the prevention of venous thromboembolism after bariatric surgery publication-title: J Thromb Haemost doi: 10.1111/jth.14263 – volume: 163 start-page: 190 year: 2018 end-page: 195 ident: CR38 article-title: The effect of bariatric surgery on direct-acting oral anticoagulant drug levels publication-title: Thromb Res doi: 10.1016/j.thromres.2017.11.006 – volume: 265 start-page: 143 issue: 1 year: 2017 end-page: 150 ident: CR4 article-title: Who should get extended thromboprophylaxis after bariatric surgery?: A risk assessment tool to guide indications for post-discharge pharmacoprophylaxis publication-title: Ann Surg doi: 10.1097/SLA.0000000000001686 – volume: 30 start-page: 1473 issue: 10 year: 2022 end-page: 1478 ident: CR36 article-title: The use of enoxaparin as venous thromboembolism prophylaxis in bariatric surgery: a retrospective cohort study publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2022.07.008 – volume: 18 start-page: 165 issue: 2 year: 2022 end-page: 174 ident: CR11 article-title: American Society for Metabolic and Bariatric Surgery Clinical Issues Committee. The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery publication-title: Surg Obes RelatDis doi: 10.1016/j.soard.2021.10.023 – volume: 60 start-page: 626 issue: 7 year: 2019 end-page: 632 ident: CR13 article-title: Comparison of apixaban and low molecular weight heparin in preventing deep venous thrombosis after total knee arthroplasty in older adults publication-title: Yonsei Med J doi: 10.3349/ymj.2019.60.7.626 – volume: 16 start-page: 141 issue: 2 year: 2010 end-page: 145 ident: CR6 article-title: Early discharge of patients with venous thromboembolism: implications regarding therapy publication-title: Clin Appl Thromb Hemost doi: 10.1177/1076029609342093 – volume: 28 start-page: 3834 issue: 12 year: 2018 end-page: 3842 ident: CR27 article-title: Failed sleeve gastrectomy: single anastomosis duodenoileal bypass or Roux-en-Y gastric bypass? publication-title: Multicenter Cohort Stud Obes Surg doi: 10.1007/s11695-018-3429-z – volume: 14 start-page: 354 issue: 3 year: 2018 end-page: 360 ident: CR30 article-title: Extended use of bemiparinas thromboprophylaxis during bariatric surgery: results of anti-factor Xa activity measurements publication-title: Surg Obes RelatDis doi: 10.1016/j.soard.2017.12.004 – volume: 28 start-page: 3809 issue: 12 year: 2018 end-page: 3814 ident: CR26 article-title: Matched short-term results of SADI versus GBP after sleeve gastrectomy publication-title: Obes Surg doi: 10.1007/s11695-018-3415-5 – volume: 51 start-page: 70 issue: 2–3 year: 2005 end-page: 78 ident: CR19 article-title: Thrombosis risk assessment as a guide to quality patient care publication-title: Dis Mon doi: 10.1016/j.disamonth.2005.02.003 – volume: 32 start-page: 4805 issue: 12 year: 2018 end-page: 4812 ident: CR10 article-title: Evaluation of VTE prophylaxis and the impact of alternate regimens on post-operative bleeding and thrombotic complications following bariatric procedures publication-title: Surg Endosc doi: 10.1007/s00464-018-6231-z – volume: 16 start-page: 416 issue: 3 year: 2018 end-page: 425 ident: CR3 article-title: The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study publication-title: Intest Res doi: 10.5217/ir.2018.16.3.416 – volume: 19 start-page: 529 issue: 4 year: 2018 ident: 7100_CR14 publication-title: Obes Rev doi: 10.1111/obr.12647 – volume: 19 start-page: 799 issue: 8 year: 2023 ident: 7100_CR20 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2022.12.038 – volume: 7 start-page: 181 issue: 2 year: 2011 ident: 7100_CR8 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2010.12.008 – volume: 18 start-page: 791 issue: 7 year: 2008 ident: 7100_CR31 publication-title: Obes Surg doi: 10.1007/s11695-007-9382-x – volume: 16 start-page: 416 issue: 3 year: 2018 ident: 7100_CR3 publication-title: Intest Res doi: 10.5217/ir.2018.16.3.416 – volume: 71 start-page: 406 issue: 5 year: 2005 ident: 7100_CR9 publication-title: Am Surg doi: 10.1177/000313480507100508 – volume: 12 start-page: 763 issue: 9 year: 2019 ident: 7100_CR16 publication-title: Expert Rev Hematol doi: 10.1080/17474086.2019.1634542 – volume: 83 start-page: 1466 issue: 7 year: 2017 ident: 7100_CR39 publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13243 – volume: 147 start-page: 994 issue: 11 year: 2012 ident: 7100_CR17 publication-title: Arch Surg doi: 10.1001/archsurg.2012.2298 – volume: 18 start-page: 1134 issue: 9 year: 2022 ident: 7100_CR29 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2022.06.284 – volume: 22 start-page: 2384 issue: 11 year: 2008 ident: 7100_CR35 publication-title: Surg Endosc doi: 10.1007/s00464-008-0031-9 – volume: 16 start-page: 1491 issue: 10 year: 2020 ident: 7100_CR25 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2020.05.022 – volume: 16 start-page: 2008 issue: 10 year: 2018 ident: 7100_CR33 publication-title: J Thromb Haemost doi: 10.1111/jth.14263 – volume: 29 start-page: 729 issue: 2 year: 2019 ident: 7100_CR34 publication-title: Obes Surg doi: 10.1007/s11695-018-03643-0 – volume: 32 start-page: 1 issue: 7 year: 2022 ident: 7100_CR21 publication-title: Obes Surg doi: 10.1007/s11695-022-06051-7 – volume: 33 start-page: 1026 issue: 4 year: 2023 ident: 7100_CR37 publication-title: Obes Surg doi: 10.1007/s11695-023-06471-z.10.1007/s11695-023-06471-z – volume: 32 start-page: 4805 issue: 12 year: 2018 ident: 7100_CR10 publication-title: Surg Endosc doi: 10.1007/s00464-018-6231-z – volume: 30 start-page: 3961 issue: 10 year: 2020 ident: 7100_CR28 publication-title: Obes Surg doi: 10.1007/s11695-020-04764-1 – volume: 51 start-page: 70 issue: 2–3 year: 2005 ident: 7100_CR19 publication-title: Dis Mon doi: 10.1016/j.disamonth.2005.02.003 – volume: 30 start-page: 1473 issue: 10 year: 2022 ident: 7100_CR36 publication-title: Saudi Pharm J doi: 10.1016/j.jsps.2022.07.008 – volume: 37 start-page: 903 issue: 8 year: 2011 ident: 7100_CR5 publication-title: Semin Thromb Hemost doi: 10.1055/s-0031-1297369 – volume: 26 start-page: 900 issue: 4 year: 2016 ident: 7100_CR24 publication-title: Obes Surg doi: 10.1007/s11695-016-2059-6 – ident: 7100_CR22 – volume: 16 start-page: 141 issue: 2 year: 2010 ident: 7100_CR6 publication-title: Clin Appl Thromb Hemost doi: 10.1177/1076029609342093 – volume: 265 start-page: 143 issue: 1 year: 2017 ident: 7100_CR7 publication-title: Ann Surg doi: 10.1097/SLA.0000000000001686 – volume: 163 start-page: 190 year: 2018 ident: 7100_CR38 publication-title: Thromb Res doi: 10.1016/j.thromres.2017.11.006 – volume: 15 start-page: 703 issue: 5 year: 2019 ident: 7100_CR32 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2019.02.017 – volume: 60 start-page: 626 issue: 7 year: 2019 ident: 7100_CR13 publication-title: Yonsei Med J doi: 10.3349/ymj.2019.60.7.626 – volume: 265 start-page: 143 issue: 1 year: 2017 ident: 7100_CR4 publication-title: Ann Surg doi: 10.1097/SLA.0000000000001686 – volume: 18 start-page: 165 issue: 2 year: 2022 ident: 7100_CR11 publication-title: Surg Obes RelatDis doi: 10.1016/j.soard.2021.10.023 – volume: 14 start-page: 652 issue: 5 year: 2018 ident: 7100_CR12 publication-title: Surg Obes Relat Dis doi: 10.1016/j.soard.2018.01.008 – volume: 28 start-page: 3834 issue: 12 year: 2018 ident: 7100_CR27 publication-title: Multicenter Cohort Stud Obes Surg doi: 10.1007/s11695-018-3429-z – volume: 14 start-page: 354 issue: 3 year: 2018 ident: 7100_CR30 publication-title: Surg Obes RelatDis doi: 10.1016/j.soard.2017.12.004 – volume: 29 start-page: 782 issue: 3 year: 2019 ident: 7100_CR1 publication-title: Obes Surg doi: 10.1007/s11695-018-3593-1 – ident: 7100_CR2 doi: 10.1056/NEJMoa0901836 – volume: 28 start-page: 3809 issue: 12 year: 2018 ident: 7100_CR26 publication-title: Obes Surg doi: 10.1007/s11695-018-3415-5 – volume: 34 start-page: 3521 issue: 8 year: 2020 ident: 7100_CR23 publication-title: Surg Endosc doi: 10.1007/s00464-019-07134-w – volume: 23 start-page: 1362 issue: 7 year: 2019 ident: 7100_CR15 publication-title: J Gastrointest Surg doi: 10.1007/s11605-018-3951-2 – volume: 34 start-page: 1366 issue: 3 year: 2020 ident: 7100_CR18 publication-title: Surg Endosc doi: 10.1007/s00464-019-06911-x |
| SSID | ssj0021622 |
| Score | 2.4492848 |
| Snippet | Purpose
The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis... The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the... PurposeThe utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1217 |
| SubjectTerms | Aftercare Anticoagulants Aspirin Bariatric Surgery - adverse effects Blood transfusions Cardiac arrhythmia Compression therapy Disease prevention Estrogens Gastrointestinal surgery Humans Medicine Medicine & Public Health Metabolism Mortality Obesity, Morbid - surgery Original Contributions Patient Discharge Patients Postoperative Complications - epidemiology Postoperative Hemorrhage - etiology Pulmonary embolisms Surgery Thromboembolism Venous Thromboembolism - etiology |
| SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB60XryI4iu-WMGbLna7eTQHkaoVESziC29hs7vBQptoW0H6653ZJC0iekguSTbLzD6-2Zn5BuBINePMmszyIGyTm9HGPI59n6eG4GosReBic-564c2zf_savC5Ar86FobDKek10C7UpNJ2Rn6LZTcwyYRSev39wqhpF3tW6hIaqSiuYM0cxtghLLWLGasDSRbd3_zAzwURY-hUQt_M2YpsqjaZMphOhy1b2uaO84dOfW9Uv_PnLd-q2pOtVWKmwJOuUyl-DBZuvg-pWx9qM6vCyq_7YkSFZdj8qUKQD9dUfM0Sq7MWxs7Knt1ExTAuL16A_HrKa06nIWYfqh7MLtKYdjz97LFOoN-D5uvt0ecOrOgpcyyiYcGHiUBstpRKZj8azn2WG_KcB6iPDW8ukCCSs0AqxTBREuAg2MxkpHVli02nKTWjkRW63gQmbYktWtoyPzSitfKEiqZvtSMaZjEMPRC2yRFck41TrYpDM6ZFJzAmKOXFiTqYeHM--eS8pNv59e6_WRFJNt3EyHxweHM4e40Qh74fKLYozQVxD5Ito4XmwVWpw9jtJZi4CQQ9OapXOG_-7Lzv_92UXlltuOFGczx40JqNPu48QZpIeVOPyG-Yp7H8 priority: 102 providerName: ProQuest |
| Title | Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery |
| URI | https://link.springer.com/article/10.1007/s11695-024-07100-z https://www.ncbi.nlm.nih.gov/pubmed/38409623 https://www.proquest.com/docview/3040973676 https://www.proquest.com/docview/2932437499 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1708-0428 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: AFBBN dateStart: 19970201 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1708-0428 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: 7X7 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1708-0428 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: BENPR dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1708-0428 dateEnd: 20241028 omitProxy: true ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: 8C1 dateStart: 20240101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK - Czech Republic Consortium customDbUrl: eissn: 1708-0428 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: AGYKE dateStart: 19970101 isFulltext: true titleUrlDefault: http://link.springer.com providerName: Springer Nature – providerCode: PRVAVX databaseName: SpringerLink Journals (ICM) customDbUrl: eissn: 1708-0428 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0021622 issn: 0960-8923 databaseCode: U2A dateStart: 19970101 isFulltext: true titleUrlDefault: http://www.springerlink.com/journals/ providerName: Springer Nature |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fS8MwED6cgvgi_rY6RwTfNNAsbbM-zjkdiiK6yXwqaZviYLayThD_ei9puyFTwYemD02v5S5Jv-vlvgM4kbafqDhR1PVaOsyofOr7jkPDWMNVnzPX7M25vfN6A-d66A7LpLC82u1ehSTNSj1PdmOeySZ2qKGkoZ81WHE1nReO4kGzPXOzmFfEDhCb0xbilzJV5mcZ3z9HCxhzIT5qPjuXG7Be4kXSLgy8CUsq3YLV2zIivg2yW_7FJrrsLrkY5Yb7SJH7SYYaHMuPUU4QmJInQ8ZK-i-T7DXMFB7jUf5KKgqnLCVtXS6cnKPzbGj7yWORMb0Dg8tuv9OjZdkEGnHhTimLfS-KI84lSxz0lZ0kiXW41EX1J9g04xBxg2KRROgiXIFrnp1wISOhNHmOzXdhOc1StQ-EqRAlKd6MHRQjI-kwKXhktwT3E-57FrBKe0FUcorr0hbjYM6GrDUeoMYDo_Hg04LT2T1vBaPGn73rlVGCcnblAbc1S5fmmrPgeHYZ54UOdshUoToDhDGaaxEdOgv2CmPOHse1V4u4z4Kzyrpz4b-_y8H_uh_CWtOMNL3Npw7L08m7OkIEMw0bUBNDgW2rwxqw0r56vuni-bx7d__QMIP5Czsb63o |
| linkProvider | Springer Nature |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB2V9gAXRMVXoICR4AQW69hJ1ocKtXSrLW1XFWxRb65jO2KlbVI2WxX64_htHTvJrlBFbz0klySONTO253k8bwDe6Z4snC0cTdK-DzM6SaUUgubWu6uSsySczTkcpcNj8fUkOVmBv10ujD9W2c2JYaK2lfF75J8QdntmmTRLP5__or5qlI-udiU0dFtawW4GirE2sWPf_blECFdv7u2gvt_H8e5g_GVI2yoD1PAsmVNmZWqs4VyzQiC0FEVhfXQxwd4WeIttjsusY0bjSp8lGU4RvYJn2mTOc830OLZ7D9YEFxLB39r2YHT0bQH5WNrEMRAn0D76Um3aTpO8x9KQHS1ooNihV_8ujTf83Rux2rAE7j6Ch63vSrYaY1uHFVc-Bj1ot9GJr_tLdiZ1IF9y5GhWoQqn-vekJugZkx-BDZaMf86qs7xyeE0n9RnpOKSqkmz5euVkG9F7qBtAvjcp20_g-E4k-hRWy6p0z4Ewl2NLjscW5VtoowXTGTe9fsZlwWUaAetEpkxLau5ra0zVko7Zi1mhmFUQs7qK4MPim_OG0uPWtzc6Tah2eNdqaYwRvF08xoHpoy26dChOhX6UJ3tERBnBs0aDi99xD6vR8YzgY6fSZeP_78uL2_vyBu4Px4cH6mBvtP8SHsTBtPwZow1Ync8u3Ct0n-b569ZGCZze9bC4Bt87KMA |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIiEuFRWv0AJGghNYXcdJvDkg1LJdtRSqSrRob8ZxbLHSNimbRUB_Gr-OGSfZFarorYfkksSx5mHPeGa-AXhpBrl3pXc8zYYUZnQ5z_Mk4UVJ5mouRRpycz4dZwdnyYdJOlmDP30tDKVV9mtiWKjL2tIZ-Q663YQsk6lsx3dpESej8buL75w6SFGktW-n0YrIkfv9E9235u3hCHn9Ko7H-6fvD3jXYYBbqdIFF2We2dJKaYRP0K1MvC8pspjiTD3e4rLALdYJa3CXV6nC5WHgpTJWOcKZGUgc9xbcVlLmlE6oJitnT2RtBAM9BD5EK6or2GnL9kQW6qITHsB1-OW_m-IVS_dKlDZsfuN7sNFZrWy3FbNNWHPVfTD73QE6o46_bDRtAuySYyfzGpk3M7-mDUObmH0JOLDs9Nu8Pi9qh9ds2pyzHj2qrtgudSpne-i3h44B7HNbrP0Azm6Eng9hvaor9xiYcAWO5GRcJjiMsSYRRkk7GCqZe5lnEYieZNp2cObUVWOmV0DMRGaNZNaBzPoygtfLby5aMI9r397uOaE7xW70SgwjeLF8jCpJcRZTOSSnRguKYB7Rl4zgUcvB5e8kOdRockbwpmfpavD_z-XJ9XN5DndQGfTHw-OjLbgbB8mi5KJtWF_Mf7inaDctimdBQBl8vWmN-AuxBiZa |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Extended+Post+Discharge+Prophylaxis+for+Venous+Thromboembolism+Prevention+After+Bariatric+Surgery&rft.jtitle=Obesity+surgery&rft.au=Guzman-Pruneda%2C+Francisco+A.&rft.au=Garcia%2C+Ambar&rft.au=Crum%2C+Robert+W.&rft.au=Chen%2C+Theresa&rft.date=2024-04-01&rft.pub=Springer+US&rft.issn=0960-8923&rft.eissn=1708-0428&rft.volume=34&rft.issue=4&rft.spage=1217&rft.epage=1223&rft_id=info:doi/10.1007%2Fs11695-024-07100-z&rft.externalDocID=10_1007_s11695_024_07100_z |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-8923&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-8923&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-8923&client=summon |